Hemophilia
Hemophilia
FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.
Data Elements
DEMOGRAPHICS
- Diagnosis
- Age
- Gender
- Race / Ethnicity
- BMI
- Height / Weight
PT CHARACTERISTICS
- Hemophilia Severity
- IV Access Method
- Target Joints
- Prophylaxis vs. Breakthrough Bleeding Products
- Inhibitor Use
- Last Bleed Date
- Number of Bleeds
PRIOR HISTORY
- First Diagnosis of Hemophilia Date
- Prior Regimen
- Prior Treatment Status (new to therapy or refill)
- Duration of Therapy
- Reason for Switch
PT ADHERENCE
- Current Therapy
- Duration
- Dose
- Prophylaxis Product Use
- Bleeding Product Use
- % Doses Taken
- % Doses Missed
PROVIDERS
- Type (Physician, NP, PA)
- Specialty
- Academic vs Community
- Specialty Pharmacy vs. Hemophilia Treatment Center
PAYERS
- Type (Commercial, Medicare, Medicaid, Dual Eligible)
- Payer Name
- Self-Pay and Patient Assistance
- Eligibility
- Correct PA form
- Denial Reason
PA TIMELINE
- Copay Amount
- PA Submitted Date
- Approval / Denial Date
- Appeals Submitted
DISPENSING INFO
- Current Treatment Regimen Rx
- Intended Regimen
- Actual Regimen
- Duration
- Dispensed Regimen
- Duration / Refills
- Gaps in Therapy
Patient Tear Sheet
Real Time Aggregated Data is organized and visualized at a patient level for immediate and longitudinal insight.
Click on image below for a 3 page PDF of a Patient Tear Sheet.
Publications
2022
Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A
Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo
Poster Presented at: American Thrombosis & Hemostasis Network (ATHN)
Conference dates: October 19, 2022 - October 21, 2022
Real-World Study of Rurioctocog Alfa Pegol and Emicizumab in US Clinical Practice Among Patients with Hemophilia A
Shawn X. Sun, Andrew Frick, Vinod Balasa, and Jonathan C. Roberts
DOI: 10.1080/17474086.2022.2112171
Manuscript Published in: EXPERT REVIEW OF HEMATOLOGY
Date of Publication: August 24, 2022
Effects of Pharmacokinetic Assessment on Clinical Outcomes for Patients with Moderate to Severe Hemophilia A
Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo
International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PB0688
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 9, 2022 - July 13, 2022
Effects of Pharmacokinetic Assessment on FVIII Consumption and Estimated Costs for Patients with Moderate to Severe Hemophilia A
Guy Young, Michael Callaghan, Vinod Balasa, Amit Soni, Sanjay Ahuja, Jonathan C. Roberts, Mindy L. Simpson, Andrew Frick, Ali G. Mokdad, Shan Xing, and Jorge Caicedo
International Society on Thrombosis and Haemostasis 2022; 2022 July 9-13: Abstract PB0689
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 9, 2022 - July 13, 2022
2021
A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US
Alex Cockerham, Amanda Wilson, Andrew Frick, and Pronabesh DasMahapatra
DOI: 10.1182/blood-2021-148325
Poster Presented at: American Society of Hematology (ASH)
Conference dates: December 11, 2021 - December 14, 2021
A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A
Shawn X. Sun, Andrew Frick
Poster Presented at: Academy of Managed Care Pharmacy (AMCP)
Conference dates: April 12, 2021 - April 16, 2021
A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice
Shawn X. Sun, Andrew Frick
DOI: 10.1111/hae.14236: ABS039
Poster Presented at: European Association for Haemophilia and Allied Disorders
Conference dates: February 3, 2021 - February 5, 2021
2020
Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States
Shawn X. Sun, Scott Milligan
Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 12, 2020 - July 14, 2020
A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH
DOI: 10.18553/jmcp.2020.26.4.492
Manuscript Published in: Journal of Managed Care & Specialty Pharmacy
Date of Publication: April 1, 2020
2019
Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data
Maureen Watt and Scott Milligan
DOI: 10.1182/blood-2019-124101
Poster Presented at: The American Society of Hematology (ASH)
Conference dates: December 7, 2019 - December 10, 2019
A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States
Maureen Watt and Scott Milligan
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 6, 2019 - July 10, 2019
2018
A Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States
J. Booth, M. Watt, S. Milligan, and L. Aledort
DOI: 10.18553/jmcp.2018.24.4-a.s1
Poster Presented at: Academy of Managed Care Pharmacy (AMCP)
Conference dates: April 23, 2018 - April 26, 2018
